The facility will also have cell culture bioreactors with an aggregate capacity of 60,000 litres | Photo Credit: BLOOMBERG NEWS
: TheraNym Biologics, an arm of Aurobindo Pharma, will construct a greenfield project for commissioning a large scale mammalian drug substance manufacturing facility with an investment of around $150-$175 million.
“This will be as per a new addition to the existing CMO Agreement TheraNym Biologics with Merck Sharp & Dohme Singapore Trading Pte Ltd, Singapore, (MSD),“ Aurobindo Pharma said in a release on Wednesday.
Theranym will invest around $150 million to $175 million for establishing a manufacturing facility of mammalian cell culture bioreactors with an aggregate capacity of 60,000 litres, together with requisite downstream purification infrastructure to produce Drug Substance.
“This serves to further expand the existing CMO relationship initiated pursuant to the previously disclosed arrangement in May 2024. Under this newly signed product schedule, TheraNym Biologics will construct a greenfield project for commissioning a large scale mammalian Drug Substance manufacturing facility (Unit 2) housing a total of 60 KL bioreactor capacities,’’ it said.
Published on April 15, 2026
此内容由惯性聚合(RSS阅读器)自动聚合整理，仅供阅读参考。 原文来自 — 版权归原作者所有。